

FDA Warns of Risks with Unapproved Use of Malaria Drug Qualaquin

SERIOUS SIDE EFFECTS REPORTED WHEN USED TO TREAT OR PREVENT NIGHT TIME LEG CRAMPS

The United States Food and Drug Administration today warned that the unapproved use of the malaria drug Qualaquin (quinine sulfate) to treat night time leg cramps has resulted in serious side effects and prompted the manufacturer to develop a risk management plan aimed at educating health care professionals and patients about the potential risks. Qualaquin is not FDA-approved to treat or prevent night time leg cramps.

A review of reports submitted to the FDA's Adverse Event Reporting System (AERS) between April 2005 and Oct. 1, 2008, found 38 United States cases of serious side effects associated with the use of quinine, the active drug in Qualaquin.


Quinine use resulted in serious and life-threatening reactions in 24 cases, including low level of platelets in the blood (thrombocytopenia), and hemolytic uremic syndrome/thrombotic thrombocytopenic purpura, a blood disorder that results in clots in small blood vessels around the body that can be accompanied by kidney impairment.

In some patients, these side effects resulted in permanent kidney impairment and hospitalization. Two patients died. Most of those reporting serious side effects took the drug to prevent or treat leg cramps or restless leg syndrome.

The risk management plan, called a Risk Evaluation



Early morning scenes on the University of Lagos campus, Nigeria. Nigeria is the largest malaria-endemic country in the world, and bears the burden of the greatest number of deaths, according to WHO. Pictures were taken by MJoTA Publisher while a guest of Dean of Pharmacy, Professor Dr David Ifudu and his wife Mrs Efe Ifudu RD.



Chief Lookman Sulaimon Arounfale MS, Publisher of New York Echo, invites you to celebrate the 50th anniversary of Nigerian independence in New York the first weekend in October.

New York Echo is New York's first African, Caribbean and African-American community newspaper, more on <http://www.mjota-nyecho.com>.

When you want your message read and cut out by Africans, Caribbeans and African-Americans throughout New York, and when you want New York Echo delivered by mail, contact us at New York Echo: publisher@nyecho.com; publisher@mjota.org; call or text 1-718-395-0235 or 1-609-792-1571.

REPORTING NEWS NURTURED BY TRUTH

New York ECHO

African Diaspora's Community Newspaper

FREE VOL. 1 No. 0008 Published Weekly by Lookman Group Inc. FREE

AFRICA AND AMERICA

MiMW (MJoTA Institute of Medical Writing)

trains health and science professionals in all time zones who want to work in the international pharmaceutical industry or who need to improve skills in writing documents for regulatory agencies, book reports, grant proposals, presentations, manuscripts, regulatory documents, press releases, business plans and in job and contract seeking. Class assignments are publishable in MJoTA or New York Echo.

MiMW Certificate in Medical Writing can be earned in 6 months. MiMW Certificate in Reporting Statistics can be earned in 1 month. Next class forms October 1st.

<http://www.medicalwritinginstitute.us>.

DrDodgson@medicalwritinginstitute.us

Telephone 609-792-1571.

and Mitigation Strategy (REMS), requires that patients be given a Medication Guide explaining what Quaaliquin is and is not approved for, as well as the potential side effects of the drug. The company is also required to issue a Dear Health Care Provider Letter warning of the potential risk of serious and life-threatening blood-related (hematologic) reactions.

"Health care professionals and patients should be aware that FDA has not approved the use of Quaaliquin for the treatment or prevention of night time leg cramps," said Edward Cox MD, MPH, director, Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research. "FDA has received reports that some patients have developed serious side effects when taking quinine for night time leg cramps."

Quaaliquin was approved by the FDA in August 2005 to treat uncomplicated malaria caused by the parasite

Plasmodium falciparum, an infection that can be life-threatening if untreated. According to the U.S. Centers for Disease Control and Prevention, about 1,500 cases of malaria are diagnosed in the United States each year, primarily resulting from travel abroad.

Quaaliquin is marketed by Philadelphia-based AR Scientific.

Health care professionals and patients may report serious adverse events (side effects) to the FDA's MedWatch Adverse Event Reporting program online at www.fda.gov, by regular mail, fax, or phone.

By mail, send postage-paid, pre-addressed Form FDA 3500 to the address on the pre-addressed form.

Fax: 800-FDA-0178

Phone: 800-332-1088

CDC: CENTERS FOR DISEASE CONTROL AND PREVENTION.

FDA: FOOD AND DRUG ADMINISTRATION

New York to Lagos

NO
STOPS

Only Arik Air flies non-stop from New York JFK to Nigeria. And only Arik offers two free checked bags weighing 66lbs each in Economy Class or three in Premier. To fly world class, contact your travel agent or call 1-877-900-ARIK.

Operated by our partner, HI Fly Transportes Aereos S.A.

Arik
arikair.com